

FISH & RICHARDSON P.C.

225 Franklin Street
Boston, Massachusetts
02110-2804

Telephone
617 542-5070

Facsimile
617 542-8906

Web Site
www.fr.com

Date September 18, 2000

To Examiner James Ketter
Art Unit 1636
U.S. Patent and Trademark Office

Facsimile number 07236-01300004 / 703-305-7939

From Janis K. Fraser, Ph.D., J.D.

Re U.S. Patent Application No. 09/225,718
Applicant: Douglas A. Treco et al.
Filing Date: January 6, 1999
Attorney/Docket No.: 07236-013004

Number of pages
including this page

//

Message

REC'D
FAX CENTER
TC 1600

ML
9/18/00

NOTE: This facsimile is intended for the addressee only and may contain privileged or confidential information. If you have received this facsimile in error, please immediately call us collect at 617 542-5070 to arrange for its return. Thank you.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Douglas A. Treco et al.
Serial No. : 09/225,718
Filed : January 6, 1999
Title : TRANSKARYOTIC PRODUCTION AND DELIVERY OF DNASE

Art Unit : 1636
Examiner : J. Ketter

Commissioner for Patents
Washington, D.C. 20231

THIRD PRELIMINARY AMENDMENT

Prior to examination, please amend the application as follows:

In the Claims:

Cancel claims 58-65 without prejudice. Add the following new claims.

66. A method of providing a therapeutic product to a mammal, comprising introducing into the mammal a vertebrate cell which produces the therapeutic product, the cell being generated by an *in vitro* process comprising:

(a) providing a vertebrate cell the genomic DNA of which comprises an endogenous gene;

(b) providing a DNA construct comprising:

(1) a targeting sequence homologous to a target site within or upstream of the endogenous gene,

(2) an exogenous regulatory sequence,

(3) an exon, and

(4) an unpaired splice-donor site at the 3' end of the exon; and

(c) transfecting the vertebrate cell with the construct, thereby generating a homologously recombinant cell in which the exogenous regulatory sequence controls expression of a transcript comprising sequence corresponding to the construct-derived exon, the construct-derived splice-donor site, and all endogenous exons of the endogenous gene to produce an RNA transcript that encodes the therapeutic product.

67. The method of claim 66, wherein the vertebrate cell is a primary or secondary cell.

68. The method of claim 67, wherein the primary or secondary cell is a mammalian cell.

CERTIFICATE OF TRANSMISSION BY FACSIMILE

I hereby certify that this correspondence is being transmitted by facsimile to the Patent and Trademark Office on the date indicated below.

Date of Transmission

September 18, 2000

Signature

KATHLEEN PHILPOT

Typed or Printed Name of Person Signing Certificate